 Company backed by billionaire Li Ka-shing secures cornerstone investors for more than half of its 600 million secondary listing in its home market. Hutchmed expects to spend 300 million on RD this year, up 72 from 2020, and is looking to further expand its capital market access to other stock exchange to give it more access to other funding sources. 